{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-029736","form_type":"8-K","ticker":"KYNB","cik":"0000921299","company_name":"KYNTRA BIO, INC.","filed_at":"2023-06-26T23:59:59+00:00","discovered_at":"2026-05-14T18:03:42.822298+00:00","generated_at":"2026-06-13T17:28:41.930349+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.9,"calibrated_materiality_score":0.9,"confidence":"high","headline":"FibroGen Phase 3 ZEPHYRUS-1 trial of pamrevlumab for IPF fails primary endpoint","bullets":["Phase 3 ZEPHYRUS-1 did not meet primary endpoint: change in FVC at week 48 (p=0.29); placebo-corrected difference 70 ml.","Secondary endpoint (disease progression or death) also not met (HR=0.78, 95% CI 0.52-1.15).","ZEPHYRUS-2 Phase 3 IPF trial will be discontinued based on these results.","Company plans cost reductions to extend cash runway into 2026; roxadustat commercialization continues.","Upcoming milestones: DMD data 3Q 2023, pancreatic cancer data 1H 2024, new IND filings."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-029736","json":"https://secwatch.observer/filing/0000950170-23-029736.json","markdown":"https://secwatch.observer/filing/0000950170-23-029736.md","text":"https://secwatch.observer/filing/0000950170-23-029736.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/921299/000095017023029736/0000950170-23-029736-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/921299/000095017023029736/fgen-20230626.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-13T17:28:41.930349+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}